| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 23.58% | Citigroup | $0.4 → $0.25 | Maintains | Neutral |
| 08/16/2023 | 48.29% | HC Wainwright & Co. | $6 → $0.3 | Downgrades | Buy → Neutral |
| 08/10/2023 | 147.16% | Piper Sandler | $6 → $0.5 | Downgrades | Overweight → Neutral |
| 07/17/2023 | 2865.89% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/22/2023 | 2865.89% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 02/21/2023 | 2865.89% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
| 02/16/2023 | 3360.21% | B of A Securities | $2 → $7 | Upgrades | Underperform → Buy |
| 02/16/2023 | 4843.15% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 05/27/2022 | 888.63% | B of A Securities | → $2 | Downgrades | Neutral → Underperform |
| 12/20/2021 | 9786.31% | Citigroup | $11 → $20 | Maintains | Buy |
| 12/15/2021 | 4843.15% | HC Wainwright & Co. | → $10 | Upgrades | Neutral → Buy |
| 12/15/2021 | 7314.73% | BTIG | → $15 | Upgrades | Neutral → Buy |
| 10/20/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 10/19/2021 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/16/2020 | 7314.73% | Credit Suisse | $9 → $15 | Upgrades | Neutral → Outperform |
| 12/07/2020 | 7314.73% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 11/11/2020 | 4348.84% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 07/29/2020 | 3854.52% | Credit Suisse | $14 → $8 | Maintains | Neutral |
| 12/02/2019 | 14729.46% | BTIG | → $30 | Initiates Coverage On | → Buy |
| 12/02/2019 | 7314.73% | B of A Securities | → $15 | Initiates Coverage On | → Buy |
| 12/02/2019 | 9786.31% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 12/02/2019 | 6820.42% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
What is the target price for Galera Therapeutics (GRTX)?
The latest price target for Galera Therapeutics (NASDAQ: GRTX) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $0.25 expecting GRTX to rise to within 12 months (a possible 23.58% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Galera Therapeutics (GRTX)?
The latest analyst rating for Galera Therapeutics (NASDAQ: GRTX) was provided by Citigroup, and Galera Therapeutics maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Galera Therapeutics (GRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galera Therapeutics was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
Is the Analyst Rating Galera Therapeutics (GRTX) correct?
While ratings are subjective and will change, the latest Galera Therapeutics (GRTX) rating was a maintained with a price target of $0.40 to $0.25. The current price Galera Therapeutics (GRTX) is trading at is $0.20, which is out of the analyst's predicted range.